hotspot -WSS

hotspot

author：leisure time 2025-09-27 22:05:32 - browse：9

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Medicare innovation center doesn’t save money, experts say

WSS

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Delta passengers in Vegas fall sick while waiting on flight in triple

The stock market has soared this year, but will it last? Experts weigh in

A new ‘biological computer' targets cancer while sparing healthy cells

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

leisure time

hotspot

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Judge denies Trump's request for new trial in E. Jean Carroll case

Jerome Adams on the need for new antivirals for Covid

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Scientists grapple with ethics of stem cell research

Continuity nursing helped my family in our darkest PICU moments

6 solutions to address cancer drug shortages and others

Medicare details structure of new drug price negotiation program

Stanford president’s abrupt resignation sparks debate

entertainment

Judge denies Trump's request for new trial in E. Jean Carroll case

Health insurers' Q3 question: how much care are people getting?

The stability of $0 premiums in Medicare Advantage

Are infertility treatments 'essential' during the Covid

Dementia risk linked to living in disadvantaged areas: Study

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

focus

entertainment

focus

focus